SRC and neoplasm: In conclusion, lidocaine can depress immune and inflammatory response by influencing immune cells (e.g., NK cells and macrophages), reducing the release of inflammatory entities (e.g., CA3 and IL-6), inhibiting signaling pathways (e.g., Src-dependent inflammatory signaling), and damaging the inflammatory tumor microenvironment, thereby reducing and inhibiting cancer metastasis.